Vyzulta carries a retail price of roughly $565 to $580 for a single 5 mL bottle, which can last about a month when used in both eyes. That’s a striking number, especially when generic prostaglandin eye drops for glaucoma cost a fraction of the price. Several factors stack on top of each other to keep the cost high: a dual-action formulation that required costly development, layered licensing fees between multiple companies, active patent protection blocking generic competition, and a relatively small patient market.
It’s Not Just Another Prostaglandin Drop
Most prostaglandin eye drops for glaucoma work by opening one drainage route to lower eye pressure. Vyzulta works through two. When the drop hits your eye, it breaks down into two active components. One is latanoprost acid, the same compound found in generic latanoprost. It loosens connective tissue in the eye’s secondary drainage pathway (called the uveoscleral route), allowing more fluid to flow out. The second component is nitric oxide, a signaling molecule that relaxes cells in the eye’s primary drainage filter, called the trabecular meshwork. This dual approach is the core of Vyzulta’s value proposition and the reason Bausch + Lomb can price it above older generics.
Developing a molecule that delivers nitric oxide in a stable, ophthalmically safe form required years of research. The compound had to survive two large clinical trials, known as APOLLO and LUNAR, to earn FDA approval in 2017. In those trials, Vyzulta lowered eye pressure by roughly 1 to 1.4 mmHg more than timolol, a standard comparator. That edge may sound small, but in glaucoma treatment, every millimeter of mercury matters for preserving vision over decades.
Licensing Fees Built Into Every Bottle
Vyzulta wasn’t developed entirely in-house at Bausch + Lomb. The molecule was originally created by Nicox, a French pharmaceutical company, which licensed it to Bausch + Lomb in 2010. Under that deal, Bausch + Lomb pays Nicox royalties of 10% to 16% on worldwide net sales, scaling upward as annual revenue crosses predefined thresholds. Nicox, in turn, pays its own royalties to Pfizer for underlying intellectual property, which means a portion of every dollar you spend on Vyzulta passes through three corporate hands before anyone profits.
On top of royalties, Bausch + Lomb owes Nicox up to $165 million in milestone payments tied to sales targets. These obligations create a financial floor: the retail price has to be high enough for Bausch + Lomb to cover manufacturing, marketing, and these layered fees while still turning a profit. Those costs get passed directly to you at the pharmacy counter.
No Generic Competition Until 2029
The single biggest reason Vyzulta stays expensive is patent protection. According to FDA records, the last qualifying patent on latanoprostene bunod doesn’t expire until February 21, 2029. Until that date, no generic manufacturer can legally produce a cheaper version. Brand-name drugs without generic competition face almost no downward pressure on pricing, which is why Vyzulta can remain at $565+ per bottle while generic latanoprost costs pennies per day.
For context, in Canadian pricing data from 2019, Vyzulta cost about $0.30 per day compared to $0.22 per day for generic latanoprost when treating both eyes. That gap looks modest in a regulated market like Canada, but in the U.S., where drug pricing is less controlled, the difference is far more dramatic. The American retail price reflects what the market will bear in the absence of competition.
A Small Market With High Fixed Costs
Glaucoma eye drops serve a relatively narrow patient population compared to blockbuster drugs for conditions like high cholesterol or diabetes. The fixed costs of clinical trials, FDA compliance, manufacturing sterile ophthalmic solutions, and maintaining a specialty sales force don’t shrink just because fewer patients need the drug. Companies spread those costs across a smaller number of prescriptions, which pushes the per-bottle price higher. Vyzulta also competes in a crowded therapeutic space where many patients do fine on cheap generics, so its commercial audience is further narrowed to patients who need more pressure reduction than standard drops provide.
Ways to Lower Your Out-of-Pocket Cost
If you have commercial insurance, your plan may cover part of Vyzulta’s cost, though copays for branded specialty drops can still be significant. Bausch + Lomb offers a manufacturer savings program that may reduce costs for commercially insured patients. Pharmacy discount tools like GoodRx sometimes negotiate prices below the listed retail, though the savings vary by location. If you’re uninsured or underinsured, Bausch + Lomb also has a patient assistance program worth asking about.
The most practical question to bring to your eye doctor is whether the dual-action benefit of Vyzulta justifies the price difference for your specific situation. Some patients get adequate pressure control from generic latanoprost at under $20 per month. Others, particularly those whose pressure isn’t well controlled on a single-mechanism drop or who want to avoid adding a second medication, may find Vyzulta’s premium worthwhile. Your doctor can compare your pressure readings on your current regimen to help you decide whether the extra cost translates into a meaningful clinical benefit for your eyes.